Skip to main content

Advertisement

Table 2 Frequency of treatment-emergent adverse events (AEs)

From: A phase 1/2, open-label assessment of the safety, tolerability, and efficacy of transdermal cannabidiol (ZYN002) for the treatment of pediatric fragile X syndrome

All treated patients (N = 20)
Treatment-emergent adverse events Frequency (%)
Gastroenteritis 5 (25%)
Vomiting 2 (10%)
Upper respiratory tract infection 2 (10%)
Mouth ulceration 1 (5%)
Paraesthesia oral 1 (5%)
Diarrhea 1 (5%)
Application site dryness 1 (5%)
Application site rash 1 (5%)
Influenza 1 (5%)
Viral infection 1 (5%)
Viral upper respiratory tract infection 1 (5%)
Otitis media 1 (5%)
Tonsillitis 1 (5%)
Limb injury 1 (5%)
Eosinophil count abnormal 1 (5%)
Neck pain 1 (5%)
Pain in extremity 1 (5%)
Dizziness 1 (5%)
Lethargy 1 (5%)
Psychomotor hyperactivity 1 (5%)
Enuresis 1 (5%)
Stereotypy 1 (5%)
Nightmare 1 (5%)
Pruritus 1 (5%)
Eczema 1 (5%)
Rash pruritic 1 (5%)
  1. Note. Frequency reflects all reported events; individual patients may have experienced more than one AE